Australia - English - Department of Health (Therapeutic Goods Administration)

medtas pty ltd - gabapentin, quantity: 300 mg - capsule, hard - excipient ingredients: purified talc; maize starch; titanium dioxide; purified water; iron oxide yellow; gelatin; sodium lauryl sulfate - gabapentin is indicated for the treatment of partial seizures, including secondarily generalised tonic-clonic seizures, initially as add-on therapy in adults and children age 3 years and above who have not achieved adequate control with standard anti-epileptic drugs.,gabapentin is indicated for the treatment of neuropathic pain.

Australia - English - Department of Health (Therapeutic Goods Administration)

medtas pty ltd - gabapentin, quantity: 100 mg - capsule, hard - excipient ingredients: maize starch; purified talc; titanium dioxide; purified water; gelatin; sodium lauryl sulfate - gabapentin is indicated for the treatment of partial seizures, including secondarily generalised tonic-clonic seizures, initially as add-on therapy in adults and children age 3 years and above who have not achieved adequate control with standard anti-epileptic drugs.,gabapentin is indicated for the treatment of neuropathic pain.

Australia - English - Department of Health (Therapeutic Goods Administration)

medtas pty ltd - gabapentin, quantity: 400 mg - capsule, hard - excipient ingredients: maize starch; purified talc; titanium dioxide; purified water; iron oxide red; iron oxide yellow; gelatin; sodium lauryl sulfate - gabapentin is indicated for the treatment of partial seizures, including secondarily generalised tonic-clonic seizures, initially as add-on therapy in adults and children age 3 years and above who have not achieved adequate control with standard anti-epileptic drugs.,gabapentin is indicated for the treatment of neuropathic pain.

Australia - English - Department of Health (Therapeutic Goods Administration)

medtas pty ltd - gabapentin, quantity: 600 mg - tablet, film coated - excipient ingredients: magnesium stearate; hyprolose; purified talc - gabapentin b&b is indicated for the treatment of partial seizures, including secondarily generalised tonic-clonic seizures, initially as add-on therapy in adults and children age 3 years and above who have not achieved adequate control with standard anti-epileptic drugs.,gabapentin b&b is indicated for the treatment of neuropathic pain.

Australia - English - Department of Health (Therapeutic Goods Administration)

medtas pty ltd - prucalopride succinate, quantity: 2.64 mg (equivalent: prucalopride, qty 2 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; colloidal anhydrous silica; magnesium stearate; titanium dioxide; hypromellose; triacetin; iron oxide yellow; iron oxide red; macrogol 3000; indigo carmine aluminium lake - prucalopride is indicated for the treatment of chronic functional constipation in adults in whom laxatives fail to provide adequate relief. ? before prucalopride is considered patients must have tried at least two different types of laxatives from different classes (at the highest tolerated recommended doses) for at least six months, but have not had adequate relief from constipation. ? if treatment with prucalopride is not effective within four weeks, the benefit of continuing treatment should be reconsidered.

Australia - English - Department of Health (Therapeutic Goods Administration)

medtas pty ltd - prucalopride succinate, quantity: 1.32 mg (equivalent: prucalopride, qty 1 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; colloidal anhydrous silica; magnesium stearate; titanium dioxide; hypromellose; triacetin; macrogol 3000 - prucalopride is indicated for the treatment of chronic functional constipation in adults in whom laxatives fail to provide adequate relief. ? before prucalopride is considered patients must have tried at least two different types of laxatives from different classes (at the highest tolerated recommended doses) for at least six months, but have not had adequate relief from constipation. ? if treatment with prucalopride is not effective within four weeks, the benefit of continuing treatment should be reconsidered.

Australia - English - Department of Health (Therapeutic Goods Administration)

medtas pty ltd - dobutamine hydrochloride, quantity: 28 mg/ml (equivalent: dobutamine, qty 25 mg/ml) - injection, powder for - excipient ingredients: mannitol; water for injections - dobutrex is indicated is adults who require short-term treatment of cardiac failure secondary to acute myocardial infarction, or cardiac surgery.

Australia - English - Department of Health (Therapeutic Goods Administration)

medtas pty ltd - fluorouracil, quantity: 1000 mg - injection, solution - excipient ingredients: water for injections; sodium hydroxide - alone or in combination, for the palliative treatment of malignant tumours, particularly of the,breast, colon or rectum; and in the treatment of gastric, primary hepatic, pancreatic, uterine,(cervical particularly), ovarian and bladder carcinomas.,fluorouracil should only be used when other proven measures have failed or are considered,impractical.

Australia - English - Department of Health (Therapeutic Goods Administration)

medtas pty ltd - fluorouracil, quantity: 500 mg - injection, solution - excipient ingredients: sodium hydroxide; water for injections - alone or in combination, for the palliative treatment of malignant tumours, particularly of the,breast, colon or rectum; and in the treatment of gastric, primary hepatic, pancreatic, uterine,(cervical particularly), ovarian and bladder carcinomas.,fluorouracil should only be used when other proven measures have failed or are considered,impractical.

Australia - English - Department of Health (Therapeutic Goods Administration)

medtas pty ltd - fluorouracil, quantity: 5 g - injection, solution - excipient ingredients: sodium hydroxide; water for injections - alone or in combination, for the palliative treatment of malignant tumours, particularly of the,breast, colon or rectum; and in the treatment of gastric, primary hepatic, pancreatic, uterine,(cervical particularly), ovarian and bladder carcinomas.,fluorouracil should only be used when other proven measures have failed or are considered,impractical.